The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 28, 2015

Filed:

Dec. 13, 2004
Applicants:

John Foekens, Rotterdam, NL;

Nadia Harbeck, Otterfing, DE;

Thomas Koenig, Berlin, DE;

Sabine Maier, Brussels, BE;

John W. Martens, Rotterdam, NL;

Fabian Model, Berlin, DE;

Inko Nimmrich, Berlin, DE;

Manfred Schmitt, Munich, DE;

Ralf Lesche, Berlin, DE;

Dimo Dietrich, Berlin, DE;

Volkmar Mueller, Hamburg, DE;

Antje Kluth Lukas, Wentorf, DE;

Ina Schwope, Berlin, DE;

Oliver Hartmann, Berlin, DE;

Peter Adorjan, Berlin, DE;

Almuth Marx, Nuremberg, DE;

Heinz Hoefler, Munich, DE;

Inventors:

John Foekens, Rotterdam, NL;

Nadia Harbeck, Otterfing, DE;

Thomas Koenig, Berlin, DE;

Sabine Maier, Brussels, BE;

John W. Martens, Rotterdam, NL;

Fabian Model, Berlin, DE;

Inko Nimmrich, Berlin, DE;

Manfred Schmitt, Munich, DE;

Ralf Lesche, Berlin, DE;

Dimo Dietrich, Berlin, DE;

Volkmar Mueller, Hamburg, DE;

Antje Kluth Lukas, Wentorf, DE;

Ina Schwope, Berlin, DE;

Oliver Hartmann, Berlin, DE;

Peter Adorjan, Berlin, DE;

Almuth Marx, Nuremberg, DE;

Heinz Hoefler, Munich, DE;

Assignee:

Epigenomics AG, Berlin, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01);
Abstract

The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the disease free survival and/or response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.


Find Patent Forward Citations

Loading…